Ads
related to: hedgehog pathway and basal cell carcinoma treatment- How ODOMZO Works
Discover why
the molecule matters.
- Dosing & Administration
See recommended dosing.
Schedule & guidance available.
- Patient Case Studies
View response rate & duration data.
See case study details.
- Safety Information
See adverse reactions.
View lab abnormalities.
- Trial Design
Pivotal study evaluated ODOMZO.
See study results.
- Complete Response Results
See objective response rate info.
Over 30-month analysis.
- How ODOMZO Works
Search results
Results From The WOW.Com Content Network
[10] [11] [12] At least three Hedgehog pathway inhibitors have been approved by the Food and Drug Administration (FDA) for cancer treatment. [12] These include vismodegib [13] and sonidegib, [14] both inhibitors of Smoothened (SMO), which are being used for the treatment of basal cell carcinoma.
The Hedgehog signaling pathway is a signaling pathway that transmits information to embryonic cells required for proper cell differentiation. Different parts of the embryo have different concentrations of hedgehog signaling proteins. The pathway also has roles in the adult. Diseases associated with the malfunction of this pathway include cancer ...
Vismodegib, sold under the brand name Erivedge, is a medication used for the treatment of basal-cell carcinoma (BCC). [3] The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration (FDA) approval. [4]
Basal-cell carcinoma (BCC), also known as basal-cell cancer, basalioma [7] or rodent ulcer, [8] is the most common type of skin cancer. [2] It often appears as a painless raised area of skin, which may be shiny with small blood vessels running over it. [1] It may also present as a raised area with ulceration. [1]
It also is the target of vismodegib, the first hedgehog pathway inhibitor to be approved by the U.S. Food and Drug Administration (FDA). [8] Smoothened (Smo) is a key transmembrane protein that is a key component of the hedgehog signaling pathway, a cell-cell communication system critical for embryonic development and adult tissue homeostasis.
It was approved for medical use in the United States and in the European Union in 2015 [7] [1] [8] [9]. It is indicated for the treatment of adults with locally advanced basal-cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.
Ad
related to: hedgehog pathway and basal cell carcinoma treatment